| |
Figure 6. Dystroglycan depletion does not disrupt the myogenic signaling pathway. A-C: Sections of control explant at stage 24 equivalent. A: Immunostaining with the 12/101 antibodies. B: Hoechst. Some nuclei are aligned. C: Merge. D-F: Sections of morpholino (MO) -injected explant at stage 24 equivalent. D: Immunodetection with the 12/101 antibodies. No staining is observed. E: Hoechst. F: Merge. G-H prime : Whole-mount in situ hybridization of XMyoD. G: Stage 24, dorsal view of unilaterally injected embryo (injected side on the right). H: Stage 28, lateral view of the control side. H prime : Stage 28, lateral view of the injected side. The intersomitic junctions are disorganized (white arrows). I: Stage 24, frontal section, immunodetection of the XMyoD protein (injected side at the right). J,K: Stage 24 equivalent, whole-mount in situ hybridization of XMyoD. J: Control explant. K: MO-injected explant. L,M: Stage 24 equivalent, immunodetection of the MyoD protein. L: Control explant. M: MO-injected explant. N-N prime : Stage 28, whole-mount in situ hybridization of XMRF4. N: Lateral view of the control side. N prime : Lateral view of the injected side. O-P prime : Stage 28, immunodetection of the MRF4 protein. O: Frontal section (injected side on the right). P: Control explant. P prime : MO-injected explant. WT, wild-type; Mo, injected side. Scale bar = 70 mu m. |
